BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 7663658)

  • 1. [Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis].
    Puchelle E; Zahm JM
    Arch Pediatr; 1995 Jul; 2(7):670-3. PubMed ID: 7663658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
    Zahm JM; Girod de Bentzmann S; Deneuville E; Perrot-Minnot C; Dabadie A; Pennaforte F; Roussey M; Shak S; Puchelle E
    Eur Respir J; 1995 Mar; 8(3):381-6. PubMed ID: 7789481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rhDNase on purulent airway secretions in chronic bronchitis.
    Puchelle E; Zahm JM; de Bentzmann S; Grosskopf C; Shak S; Mougel D; Polu JM
    Eur Respir J; 1996 Apr; 9(4):765-9. PubMed ID: 8726943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
    King M; Dasgupta B; Tomkiewicz RP; Brown NE
    Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
    Griese M; App EM; Duroux A; Burkert A; Schams A
    Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
    Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
    Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
    Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
    Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile.
    Zahm JM; Galabert C; Chaffin A; Chazalette JP; Grosskopf C; Puchelle E
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1779-84. PubMed ID: 9620905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
    Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
    Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.
    Puchelle E; de Bentzmann S; Zahm JM
    Respiration; 1995; 62 Suppl 1():2-12. PubMed ID: 7792436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
    Dasgupta B; King M
    Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
    Feng W; Garrett H; Speert DP; King M
    Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
    Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
    Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
    Shak S; Capon DJ; Hellmiss R; Marsters SA; Baker CL
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9188-92. PubMed ID: 2251263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus.
    Girod de Bentzmann S; Pierrot D; Fuchey C; Zahm JM; Morançais JL; Puchelle E
    Eur Respir J; 1993 Sep; 6(8):1156-61. PubMed ID: 8224130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mucus in cough research.
    Rubin BK
    Lung; 2010 Jan; 188 Suppl 1():S69-72. PubMed ID: 19936981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
    Shak S
    Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rhDNase on lung function and quality of life in adult cystic fibrosis patients.
    Heijerman HG; van Rossem RN; Bakker W
    Neth J Med; 1995 Jun; 46(6):293-7. PubMed ID: 7643945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
    Tarrant BJ; Le Maitre C; Romero L; Steward R; Button BM; Thompson BR; Holland AE
    Respirology; 2017 Aug; 22(6):1084-1092. PubMed ID: 28397992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.